<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The correct interpretation of metabolic response in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells to therapy requires knowledge of how <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-free tissue responds to the same treatment </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to evaluate standardized uptake values (SUVs) in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-free regions of patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> prior to and following therapy, via the use of 18-<z:chebi fb="36" ids="17051">fluoride</z:chebi> fluoro-2-deoxy-<z:chebi fb="0" ids="4167">D-glucose</z:chebi> (<z:chebi fb="0" ids="36939">18F</z:chebi>-FDG) <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography/computed tomography (PET/CT) </plain></SENT>
<SENT sid="2" pm="."><plain>On baseline <z:chebi fb="0" ids="36939">18F</z:chebi>-FDG PET/CT scans (n=51), volumes of interest (VOI) were obtained from <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-free tissue (aortic arch, liver and spleen) and SUVs normalized to total body mass were registered </plain></SENT>
<SENT sid="3" pm="."><plain>The procedure was repeated for a follow-up scan two weeks following a single administration of the third-line treatment with irinotecan plus cetuximab </plain></SENT>
<SENT sid="4" pm="."><plain>The mean differences in SUV prior to and following therapy were non-significant (P&gt;0.05) in <z:hpo ids='HP_0000001'>all</z:hpo> the registered <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-free regions </plain></SENT>
<SENT sid="5" pm="."><plain>Correlation coefficients indicated a significant result between the variables (0.74-0.84; P&lt;0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>This study suggests that the early assessment of metabolic response may be made following the administration of third-line therapy with irinotecan plus cetuximab in patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> refractory to second-line treatment with irinotecan </plain></SENT>
</text></document>